To require the Secretary of State, in consultation with the Secretary of Health and Human Services and other relevant departments and agencies, as appropriate, to formulate a strategy for the Federal Government to secure support from foreign countries, multilateral organizations, and other appropriate entities to facilitate the development and commercialization of qualified pandemic or epidemic products, and for other purposes.

HR7879, the "SUPER BUGS Act of 2026," requires the Secretary of State, in consultation with the Secretary of Health and Human Services, to formulate a strategy for securing international support to develop and commercialize qualified pandemic or epidemic products. This bill establishes a framework for the Federal Government to actively facilitate global partnerships, which directly translates into expanded market opportunities and reduced development risks for companies operating in the pandemic preparedness space. The focus is on preventing, detecting, and containing infectious disease threats globally, which directly benefits companies with established product pipelines and manufacturing capabilities for vaccines, therapeutics, and diagnostics. The money trail for this initiative is indirect but significant. While the bill does not appropriate specific funds, it mandates a strategy to "secure support from foreign countries, multilateral organizations, and other appropriate entities." This support will manifest as international grants, procurement contracts, and co-development agreements, which will flow to companies capable of delivering these products. The U.S. government's role as a facilitator means it will actively work to connect U.S. companies with international funding and market access. Companies with strong R&D pipelines in infectious diseases and existing global supply chain infrastructure are best positioned to capture these opportunities. Historically, government initiatives to accelerate medical countermeasure development have provided substantial boosts to the sector. For example, during the COVID-19 pandemic, Operation Warp Speed in 2020 provided billions in funding and procurement guarantees to companies like Pfizer ($PFE), Moderna ($MRNA), and Johnson & Johnson ($JNJ). This led to rapid vaccine development and significant revenue streams for these companies. While HR7879 is not a direct funding bill, it establishes a strategic framework that will lead to similar international funding and procurement opportunities. The U.S. government's commitment to global health security, as outlined in the bill's findings, signals sustained support for this sector. Specific winners include large pharmaceutical companies with established vaccine and therapeutic platforms such as Pfizer ($PFE), Moderna ($MRNA), and Johnson & Johnson ($JNJ). Biotechnology firms focused on infectious diseases like Gilead Sciences ($GILD) also stand to gain. Diagnostic companies such as Abbott Laboratories ($ABT) and Thermo Fisher Scientific ($TMO), and medical device manufacturers like Becton, Dickinson and Company ($BDX) will benefit from increased global demand for testing and medical supplies. There are no clear losers from this legislation, as it aims to expand opportunities for all qualified entities. This bill has been referred to the House Committee on Foreign Affairs. The next step is committee consideration and potential markup. Given the bipartisan sponsorship (Rep. Levin [D-CA-49] and Rep. Valadao), the bill has a reasonable chance of advancing. If it passes the House, it will move to the Senate. The timeline for passage is uncertain, but the mandate for a strategy indicates a long-term commitment to global pandemic preparedness.